Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the 13C-Urea Breath Test in Helicobacter pylori-Positive Patients.

Background and Aim: Vonoprazan (VPZ) is a new oral potassium-competitive acid blocker that has recently become available. The aim of this study was to investigate the effects of VPZ on the urease activity of H. pylori as measured by the 13C-urea breath test (13C-UBT).Patients and Methods: A total of...

Descripción completa

Detalles Bibliográficos
Publicado en:Digestive Diseases & Sciences Vol. 62; no. 3; pp. 739 - 746
Autores principales: Takimoto, Mayu, Tomita, Toshihiko, Yamasaki, Takahisa, Fukui, Shota, Taki, Masato, Okugawa, Takuya, Kondo, Takashi, Kono, Tomoaki, Tozawa, Katsuyuki, Arai, Eitatsu, Ohda, Yoshio, Oshima, Tadayuki, Fukui, Hirokazu, Watari, Jiro, Miwa, Hiroto
Formato: research randomized controlled trial Journal Article
Publicado: Springer Nature Mar2017
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=121387070&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 121387070
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01632116
        1VP
      jtl: Digestive Diseases & Sciences
      issn: 01632116
      maglogo: N
    pubinfo:
      dt: Mar2017
      vid: 62
      iid: 3
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        121387070
        121387070
        143998112
        NLM28083842
        121387070
        10.1007/s10620-016-4439-0
        NLM28083842
        121387070
      ppf: 739
      ppct: 7
      formats:
      tig:
        atl: Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the 13C-Urea Breath Test in Helicobacter pylori-Positive Patients.
      aug:
        au:
          Takimoto, Mayu
          Tomita, Toshihiko
          Yamasaki, Takahisa
          Fukui, Shota
          Taki, Masato
          Okugawa, Takuya
          Kondo, Takashi
          Kono, Tomoaki
          Tozawa, Katsuyuki
          Arai, Eitatsu
          Ohda, Yoshio
          Oshima, Tadayuki
          Fukui, Hirokazu
          Watari, Jiro
          Miwa, Hiroto
        affil: Division of Gastroenterology, Department of Internal Medicine , Hyogo College of Medicine , 1-1, Mukogawa-cho Nishinomiya 663-8501 Japan
      sug:
        subj:
          Helicobacter Infections Drug Therapy
          Helicobacter Infections Diagnosis
          Heterocyclic Compounds Adverse Effects
          Lansoprazole Administration and Dosage
          Sulfonamides Administration and Dosage
          Helicobacter Pylori
          Helicobacter Pylori Drug Effects
          Sulfonamides Adverse Effects
          Heterocyclic Compounds Administration and Dosage
          Lansoprazole Adverse Effects
          Helicobacter Infections Microbiology
          Drug Monitoring Methods
          Aged
          Proton Pump Inhibitors Administration and Dosage
          Proton Pump Inhibitors Adverse Effects
          Female
          Urease Metabolism
          Adult
          Middle Age
          Breath Tests Methods
          Male
          Human
          Treatment Outcomes
          Validation Studies
          Comparative Studies
          Evaluation Research
          Multicenter Studies
          Randomized Controlled Trials
          Aged: 65+ years
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Female
          Male
      ab: Background and Aim: Vonoprazan (VPZ) is a new oral potassium-competitive acid blocker that has recently become available. The aim of this study was to investigate the effects of VPZ on the urease activity of H. pylori as measured by the 13C-urea breath test (13C-UBT).Patients and Methods: A total of 60 patients (26 men, 34 women; mean age 53.2 ± 13.6 years) who were diagnosed as H. pylori-positive were recruited. The patients were randomly allocated to three treatment groups: lansoprazole (LPZ) 30 mg (n = 20), VPZ 20 mg (n = 20) once daily for 3 weeks, or the control group (n = 20). The 13C-UBT was carried out at baseline and after 3 weeks of treatment, and the baseline and after treatment results then compared. Δ13C‰ ≥ 2.5‰ was considered H. pylori-positive.Results: Four patients failed to complete the medication and were omitted from the analysis; data from the LPZ group (n = 18), VPZ group (n = 18), and control group (n = 20) were analyzed. The control group showed no significant change in 13C-UBT data between baseline and the completion of 3-week treatment (baseline: 26.6 ± 23.0‰, completion: 21.1 ± 13.1‰). The 13C-UBT data at week 3 were significantly decreased in both the VPZ group (baseline: 32.8 ± 22.7‰, completion: 7.6 ± 9.2‰, p = 0.0002) and the LPZ group (baseline: 41.8 ± 33.4‰; completion: 9.6 ± 8.8‰, p = 0.0006) compared to baseline.Conclusions: VPZ treatment reduced the value of UBT, warning that UBT for patients with VPZ treatment should be evaluated carefully.
      pubtype: Academic Journal
      doctype:
        research
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N